Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Clinical effectiveness of the START (STrAtegies for RelaTives) psychological intervention for family carers and the effects on the cost of care for people with dementia: 6-year follow-up of a randomised controlled trial.

Livingston G, Manela M, O'Keeffe A, Rapaport P, Cooper C, Knapp M, King D, Romeo R, Walker Z, Hoe J, Mummery C, Barber J.

Br J Psychiatry. 2019 Jul 12:1-8. doi: 10.1192/bjp.2019.160. [Epub ahead of print]

PMID:
31298169
2.

Rate of Cognitive Decline in Alzheimer's Disease Stratified by Age.

Stanley K, Whitfield T, Kuchenbaecker K, Sanders O, Stevens T, Walker Z.

J Alzheimers Dis. 2019;69(4):1153-1160. doi: 10.3233/JAD-181047.

PMID:
31127765
3.

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).

Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Brooks DJ, Passmore AP, Ballard C, Edison P.

Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x.

4.

Author's reply to: Difficulties of diagnosing and managing dementia in people with Down syndrome.

Eady N, Sheehan R, Rantell K, Sinai A, Bernal J, Bohnen I, Bonell S, Courtenay K, Dodd K, Gazizova D, Hassiotis A, Hillier R, McBrien J, Mukherji K, Naeem A, Perez-Achiaga N, Sharma V, Thomas D, Walker Z, McCarthy J, Strydom A.

Br J Psychiatry. 2018 Nov;213(5):669. doi: 10.1192/bjp.2018.208. No abstract available.

PMID:
30741135
5.

Author's reply.

Sheehan R, Eady N, Rantell K, Sinai A, Bernal J, Bohnen I, Bonell S, Courtenay K, Dodd K, Gazizova D, Hassiotis A, Hillier R, McBrien J, Mukherji K, Naeem A, Perez-Achiaga N, Sharma V, Thomas D, Walker Z, McCarthy J, Strydom A.

Br J Psychiatry. 2018 Nov;213(5):667-668. doi: 10.1192/bjp.2018.194. No abstract available.

PMID:
30741134
6.

The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD).

Marchant NL, Barnhofer T, Klimecki OM, Poisnel G, Lutz A, Arenaza-Urquijo E, Collette F, Wirth M, Schild AK, Coll-Padrós N, Reyrolle L, Horney D, Krolak-Salmon P, Molinuevo JL, Walker Z, Maillard A, Frison E, Jessen F, Chételat G; SCD-WELL Medit-Ageing Research Group.

Alzheimers Dement (N Y). 2018 Dec 14;4:737-745. doi: 10.1016/j.trci.2018.10.010. eCollection 2018.

7.

A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium.

Oppedal K, Ferreira D, Cavallin L, Lemstra AW, Ten Kate M, Padovani A, Rektorova I, Bonanni L, Wahlund LO, Engedal K, Nobili F, Kramberger M, Taylor JP, Hort J, Snædal J, Blanc F, Walker Z, Antonini A, Westman E, Aarsland D; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Mar;15(3):400-409. doi: 10.1016/j.jalz.2018.09.011. Epub 2018 Nov 12.

PMID:
30439333
8.

AMYPAD Diagnostic and Patient Management Study: Rationale and design.

Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Lopes Alves I, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott JM, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N.

Alzheimers Dement. 2019 Mar;15(3):388-399. doi: 10.1016/j.jalz.2018.09.003. Epub 2018 Oct 16.

9.

Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.

Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, Quinn L, Mok TH, Dimitriadis A, Norsworthy P, Bass N, Carter J, Walker Z, Kipps C, Coulthard E, Polke JM, Bernal-Quiros M, Denning N, Thomas R, Raybould R, Williams J, Mummery CJ, Wild EJ, Houlden H, Tabrizi SJ, Rossor MN, Hummerich H, Warren JD, Rowe JB, Rohrer JD, Schott JM, Fox NC, Collinge J, Mead S.

Mol Psychiatry. 2018 Oct 2. doi: 10.1038/s41380-018-0224-0. [Epub ahead of print]

10.

Determining the Initiation of Opiate Misuse Resulting in Opioid Use Disorder in Pregnant Women.

Walker ZW, Vinson AR, Babcock D, Benjamin T, Haas DM.

J Psychoactive Drugs. 2018 Sep-Oct;50(4):331-338. doi: 10.1080/02791072.2018.1497235. Epub 2018 Aug 8.

PMID:
30089441
11.

Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.

Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R, Hinz R, Biju M, Kuruvilla T, Brooks DJ, Edison P.

Brain. 2018 Sep 1;141(9):2740-2754. doi: 10.1093/brain/awy188.

PMID:
30052812
12.

European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus.

Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, Walker Z, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Neurol. 2018 Oct;25(10):1201-1217. doi: 10.1111/ene.13728. Epub 2018 Jul 20.

PMID:
29932266
13.

Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.

Wolk DA, Sadowsky C, Safirstein B, Rinne JO, Duara R, Perry R, Agronin M, Gamez J, Shi J, Ivanoiu A, Minthon L, Walker Z, Hasselbalch S, Holmes C, Sabbagh M, Albert M, Fleisher A, Loughlin P, Triau E, Frey K, Høgh P, Bozoki A, Bullock R, Salmon E, Farrar G, Buckley CJ, Zanette M, Sherwin PF, Cherubini A, Inglis F.

JAMA Neurol. 2018 Sep 1;75(9):1114-1123. doi: 10.1001/jamaneurol.2018.0894.

14.

Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, Bouwman F, Drzezga A, Nestor P, Boccardi M, Altomare D, Festari C, Nobili F; EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1534-1545. doi: 10.1007/s00259-018-4031-2. Epub 2018 May 19. Review.

15.

Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.

Drzezga A, Altomare D, Festari C, Arbizu J, Orini S, Herholz K, Nestor P, Agosta F, Bouwman F, Nobili F, Walker Z, Frisoni GB, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1487-1496. doi: 10.1007/s00259-018-4032-1. Epub 2018 May 13. Review.

PMID:
29756163
16.

Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia.

Bouwman F, Orini S, Gandolfo F, Altomare D, Festari C, Agosta F, Arbizu J, Drzezga A, Nestor P, Nobili F, Walker Z, Morbelli S, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1526-1533. doi: 10.1007/s00259-018-4034-z. Epub 2018 May 9.

17.

Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, Bouwman F, Orini S, Law I, Agosta F, Arbizu J, Boccardi M, Nobili F, Frisoni GB; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1509-1525. doi: 10.1007/s00259-018-4035-y. Epub 2018 May 7. Review.

PMID:
29736698
18.

Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders.

Nobili F, Festari C, Altomare D, Agosta F, Orini S, Van Laere K, Arbizu J, Bouwman F, Drzezga A, Nestor P, Walker Z, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1557-1566. doi: 10.1007/s00259-018-4030-3. Epub 2018 May 2. Review.

PMID:
29721650
19.

Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.

Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, Arbizu J, Bouwman F, Drzezga A, Nestor P, Nobili F, Walker Z, Pagani M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1546-1556. doi: 10.1007/s00259-018-4033-0. Epub 2018 May 1. Review.

PMID:
29717332
20.

Clinical utility of FDG-PET for the clinical diagnosis in MCI.

Arbizu J, Festari C, Altomare D, Walker Z, Bouwman F, Rivolta J, Orini S, Barthel H, Agosta F, Drzezga A, Nestor P, Boccardi M, Frisoni GB, Nobili F; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1497-1508. doi: 10.1007/s00259-018-4039-7. Epub 2018 Apr 27. Review.

PMID:
29704037
21.

Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study.

Eady N, Sheehan R, Rantell K, Sinai A, Bernal J, Bohnen I, Bonell S, Courtenay K, Dodd K, Gazizova D, Hassiotis A, Hillier R, McBrien J, Mukherji K, Naeem A, Perez-Achiaga N, Sharma V, Thomas D, Walker Z, McCarthy J, Strydom A.

Br J Psychiatry. 2018 Mar;212(3):155-160. doi: 10.1192/bjp.2017.21.

PMID:
29486820
22.

Data quality, floor and ceiling effects, and test-retest reliability of the Mild Cognitive Impairment Questionnaire.

Dean K, Walker Z, Jenkinson C.

Patient Relat Outcome Meas. 2018 Jan 15;9:43-47. doi: 10.2147/PROM.S145676. eCollection 2018.

23.

Predictors of Age of Diagnosis and Survival of Alzheimer's Disease in Down Syndrome.

Sinai A, Mokrysz C, Bernal J, Bohnen I, Bonell S, Courtenay K, Dodd K, Gazizova D, Hassiotis A, Hillier R, McBrien J, McCarthy J, Mukherji K, Naeem A, Perez-Achiaga N, Rantell K, Sharma V, Thomas D, Walker Z, Whitham S, Strydom A.

J Alzheimers Dis. 2018;61(2):717-728. doi: 10.3233/JAD-170624.

24.

Author response: Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.

Thomas AJ, Attems J, Colloby SJ, O'Brien JT, McKeith I, Walker R, Lee L, Burn D, Lett DJ, Walker Z.

Neurology. 2017 Aug 15;89(7):751. doi: 10.1212/WNL.0000000000004254. No abstract available.

PMID:
28808169
25.
26.

Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease.

Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C.

Alzheimers Dement (Amst). 2017 Jul 1;9:25-34. doi: 10.1016/j.dadm.2017.06.001. eCollection 2017.

27.

Dementia with Lewy bodies: Diagnosis is only skin deep?

Postuma RB, Walker Z.

Neurology. 2017 Jul 25;89(4):310-311. doi: 10.1212/WNL.0000000000004163. Epub 2017 Jun 30. No abstract available.

PMID:
28667177
28.

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K.

Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7. Review.

29.

Prodromal Dementia with Lewy Bodies and Prodromal Alzheimer's Disease: A Comparison of the Cognitive and Clinical Profiles.

Sadiq D, Whitfield T, Lee L, Stevens T, Costafreda S, Walker Z.

J Alzheimers Dis. 2017;58(2):463-470. doi: 10.3233/JAD-161089.

PMID:
28453473
30.

Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort.

Kramberger MG, Auestad B, Garcia-Ptacek S, Abdelnour C, Olmo JG, Walker Z, Lemstra AW, Londos E, Blanc F, Bonanni L, McKeith I, Winblad B, de Jong FJ, Nobili F, Stefanova E, Petrova M, Falup-Pecurariu C, Rektorova I, Bostantjopoulou S, Biundo R, Weintraub D, Aarsland D; E-DLB.

J Alzheimers Dis. 2017;57(3):787-795. doi: 10.3233/JAD-161109.

31.

Frontal-subcortical circuitry in social attachment and relationships: A cross-sectional fMRI ALE meta-analysis.

Lee SH, Walker ZM, Hale JB, Chen SHA.

Behav Brain Res. 2017 May 15;325(Pt B):117-130. doi: 10.1016/j.bbr.2017.02.032. Epub 2017 Feb 22.

PMID:
28237296
32.

Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.

Thomas AJ, Attems J, Colloby SJ, O'Brien JT, McKeith I, Walker R, Lee L, Burn D, Lett DJ, Walker Z.

Neurology. 2017 Jan 17;88(3):276-283. doi: 10.1212/WNL.0000000000003512. Epub 2016 Dec 9.

33.

Highly sensitive sequence specific qPCR detection of Mycobacterium tuberculosis complex in respiratory specimens.

Reed JL, Walker ZJ, Basu D, Allen V, Nicol MP, Kelso DM, McFall SM.

Tuberculosis (Edinb). 2016 Dec;101:114-124. doi: 10.1016/j.tube.2016.09.002. Epub 2016 Sep 10.

34.

Evolution of clinical features in possible DLB depending on FP-CIT SPECT result.

Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Stevens T, Whitfield T, Aarsland D, Rainer M, Padovani A; DaTSCAN DLB Phase 4 Study Group.

Neurology. 2016 Sep 6;87(10):1045-51. doi: 10.1212/WNL.0000000000003076. Epub 2016 Aug 10.

35.

Lewy body dementias.

Walker Z, Possin KL, Boeve BF, Aarsland D.

Lancet. 2015 Oct 24;386(10004):1683-97. doi: 10.1016/S0140-6736(15)00462-6. Review.

36.

Authors' reply.

Walker Z, Tabet N.

Br J Psychiatry. 2015 Oct;207(4):364-5. doi: 10.1192/bjp.207.4.364a. No abstract available.

PMID:
26429691
37.

Long-term clinical and cost-effectiveness of psychological intervention for family carers of people with dementia: a single-blind, randomised, controlled trial.

Livingston G, Barber J, Rapaport P, Knapp M, Griffin M, King D, Romeo R, Livingston D, Mummery C, Walker Z, Hoe J, Cooper C.

Lancet Psychiatry. 2014 Dec;1(7):539-48. doi: 10.1016/S2215-0366(14)00073-X. Epub 2014 Dec 3.

38.

Identification of neurodegenerative factors using translatome-regulatory network analysis.

Brichta L, Shin W, Jackson-Lewis V, Blesa J, Yap EL, Walker Z, Zhang J, Roussarie JP, Alvarez MJ, Califano A, Przedborski S, Greengard P.

Nat Neurosci. 2015 Sep;18(9):1325-33. doi: 10.1038/nn.4070. Epub 2015 Jul 27.

39.

Factors that predict cognitive decline in patients with subjective cognitive impairment.

Fonseca JA, Ducksbury R, Rodda J, Whitfield T, Nagaraj C, Suresh K, Stevens T, Walker Z.

Int Psychogeriatr. 2015 Oct;27(10):1671-7. doi: 10.1017/S1041610215000356. Epub 2015 Mar 27.

PMID:
25812703
40.

Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S.

JAMA Neurol. 2015 Mar;72(3):287-94. doi: 10.1001/jamaneurol.2014.4144.

PMID:
25622185
41.

A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).

Ballard C, Thomas A, Gerry S, Yu LM, Aarsland D, Merritt C, Corbett A, Davison C, Sharma N, Khan Z, Creese B, Loughlin P, Bannister C, Burns A, Win SN, Walker Z; MAIN-AD investigators.

J Am Med Dir Assoc. 2015 Apr;16(4):316-22. doi: 10.1016/j.jamda.2014.11.002. Epub 2014 Dec 15.

PMID:
25523285
42.

Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study.

Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, Pizzolato G, Padovani A; DaTSCAN DLB Phase 4 Study Group.

Br J Psychiatry. 2015 Feb;206(2):145-52. doi: 10.1192/bjp.bp.114.148643. Epub 2014 Nov 27.

PMID:
25431431
43.

Dementia diagnostic criteria in Down syndrome.

Sheehan R, Sinai A, Bass N, Blatchford P, Bohnen I, Bonell S, Courtenay K, Hassiotis A, Markar T, McCarthy J, Mukherji K, Naeem A, Paschos D, Perez-Achiaga N, Sharma V, Thomas D, Walker Z, Strydom A.

Int J Geriatr Psychiatry. 2015 Aug;30(8):857-63. doi: 10.1002/gps.4228. Epub 2014 Nov 3.

44.

START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementia.

Livingston G, Barber J, Rapaport P, Knapp M, Griffin M, Romeo R, King D, Livingston D, Lewis-Holmes E, Mummery C, Walker Z, Hoe J, Cooper C.

Health Technol Assess. 2014 Oct;18(61):1-242. doi: 10.3310/hta18610.

45.

Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials.

O'Brien JT, Oertel WH, McKeith IG, Grosset DG, Walker Z, Tatsch K, Tolosa E, Sherwin PF, Grachev ID.

BMJ Open. 2014 Jul 3;4(7):e005122. doi: 10.1136/bmjopen-2014-005122.

46.

Do patients with young onset Alzheimer's disease deteriorate faster than those with late onset Alzheimer's disease? A review of the literature.

Stanley K, Walker Z.

Int Psychogeriatr. 2014 Dec;26(12):1945-53. doi: 10.1017/S1041610214001173. Epub 2014 Jul 3. Review.

PMID:
24989902
47.

Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123I injection (DaTscan).

Grosset DG, Tatsch K, Oertel WH, Tolosa E, Bajaj N, Kupsch A, O'Brien JT, Seibyl J, Walker Z, Sherwin P, Chen C, Grachev ID.

J Nucl Med. 2014 Aug;55(8):1281-7. doi: 10.2967/jnumed.114.138032. Epub 2014 Jun 19.

48.

Trends in referred patient profiles in a memory clinic over 20 years.

Azam B, Whitfield TJ, Radford D, Dontham SG, Stevens T, Dannhauser T, Walker Z.

Dementia (London). 2016 Jul;15(4):789-97. doi: 10.1177/1471301214539691. Epub 2014 Jun 16.

PMID:
24939048
49.

Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging.

Seibyl JP, Kupsch A, Booij J, Grosset DG, Costa DC, Hauser RA, Darcourt J, Bajaj N, Walker Z, Marek K, McKeith I, O'Brien JT, Tatsch K, Tolosa E, Dierckx RA, Grachev ID.

J Nucl Med. 2014 Aug;55(8):1288-96. doi: 10.2967/jnumed.114.140228. Epub 2014 Jun 12.

50.

Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress.

Zis P, McHugh P, McQuillin A, Praticò D, Dickinson M, Shende S, Walker Z, Strydom A.

PLoS One. 2014 Jun 5;9(6):e97709. doi: 10.1371/journal.pone.0097709. eCollection 2014.

Supplemental Content

Loading ...
Support Center